y
188 Crk II C0853 1398 CRK P NP_005197.3 y y n/d
187 Crk-L C0978 1399 CRKL P NP_005198.1 y y n/d
534 p38 MAP Kinase, Non-Activated M8432 1432 MAPK14 M NP_001306.1 y y y
536 p38 MAPK activated (diphosphorylated
y
188 Crk II C0853 1398 CRK P NP_005197.3 y y n/d
187 Crk-L C0978 1399 CRKL P NP_005198.1 y y n/d
534 p38 MAP Kinase, Non-Activated M8432 1432 MAPK14 M NP_001306.1 y y y
536 p38 MAPK activated (diphosphorylated
y
188 Crk II C0853 1398 CRK P NP_005197.3 y y n/d
187 Crk-L C0978 1399 CRKL P NP_005198.1 y y n/d
534 p38 MAP Kinase, Non-Activated M8432 1432 MAPK14 M NP_001306.1 y y y
536 p38 MAPK activated (diphosphorylated
phospho-DAPK (pSer308) D4941 M y n/d n/d
215 DAP Kinase 2 D3191 P y y y
216 Anti Cy3+Cy5 C0992 M NA NA NA
217 Daxx D7810 P y n/d n/d
218 DcR1 D3566 P y y y
219 DcR2 D3188 P y n/d
MAB3735
Ca Ch Dr
Raf
Monoclonal Antibody
Anti-phospho-Raf-1 (Ser338) M WB Pur R IgG1 100 µg 05-534
Anti-phospho-Raf-1 (Ser338) M WB Pur M IgG 200 µg 05-538
Anti-phospho-Raf-1 (Ser338) WB Pur M
gel electrophoresis (2%
TAE gel, Figure 1). The results of the mul-
tiplex-PCR showed a clear amplification
for each target: 180 bp for stx1, 255 bp
for stx2, 384 bp for eaeA, 534 bp for
hlyA, and 910
; Rivero, I. A.;
Acosta-Martínez, D. R.; Pina-Luis, G.; Alatorre-Meda, M. Materials 2020,
13, 534.
(145) Jeon, O.; Bouhadir, K. H.; Mansour, J. M.; Alsberg, E. Biomaterials 2009,
30, 2724–2734.
; Rivero, I. A.;
Acosta-Martínez, D. R.; Pina-Luis, G.; Alatorre-Meda, M. Materials 2020,
13, 534.
(145) Jeon, O.; Bouhadir, K. H.; Mansour, J. M.; Alsberg, E. Biomaterials 2009,
30, 2724–2734.